The anti-obesity drugs rimonabant and taranabant are inverse agonists at the cannabinoid CB1 receptor and though they produced significant weight loss, both were withdrawn owing to a high incidence of depression and anxiety, which are believed to relate to the inhibition of the constitutive activity of the cannabinoid receptor.
Un exemplo son os fármacos antiobesidade rimonabant e taranabant, que son agonistas inversos no receptor CB1 cannabinoide e, aínda que ambos os dous producían unha significativa perda de peso, foron retirados do mercado debido á alta incidencia de depresión e ansiedade que producían, o cal se cre que estaba relacionado coa inhibición da actividade constitutiva do receptor cannabinoide.